Featured Story | By Paige Minemyer While payers so far have shrugged off many of the economic challenges that have plagued their provider counterparts, the economic downturn could impact them eventually, according to a new report. read more |
| |
|---|
|
Top Stories By Fraiser Kansteiner The drug pricing provisions tucked into the Inflation Reduction Act could eventually have a credit-lowering effect on the industry at large, because pharma will largely bear the brunt of the changes, the analysts said—despite the fact that several of those measures won’t come into effect for “four or more years.” read more By Andrea Park Many devicemakers have shown their support for the FDA ruling, since it allows them to market their products directly to consumers, cutting out multiple middlemen and potentially bringing their hearing aids to more people. read more By Kevin Dunleavy The lack for adequate options to treat major depressive disorder has been well documented. Then came the pandemic, adding more patients diagnosed with MDD and heightening the unmet need. With that, the timing is good for the approval of a potentially game-changing drug to treat MDD. On Friday, the FDA signed off on Axsome Therapeutics’ Auvelity, the first rapid-acting oral treatment for MDD. read more By Annalee Armstrong Just days ago, Sanofi sent its oral SERD for breast cancer to the trash can. But over in Italy, a small biotech is plodding forward with its own candidate, with the EU begining a regulatory review. read more By Ben Adams Australian biotech Immuron is showing up the brutal nature of COVID research: We have seen so many big-name successes from Pfizer, Moderna, AstraZeneca and Merck, we forget that there are also many casualties. read more By Dave Muoio Recent claims that Boston Children's Hospital and others offer genital surgery to minors have led to a spike in hostile messages and calls to clinicians and staff, according to hospitals and media reports. read more By Andrea Park A new partnership with Samsung aims to simplify EchoNous' slimmed-down ultrasound system even further—and send its costs down in the process. read more By Angus Liu Novartis’ multiple sclerosis therapy Gilenya was once proposed as a kidney disease treatment because of its ability to modulate S1P receptors. Although the drug failed in a clinical trial, scientists at the University of Virginia have now found an alternative way to target the same pathway. read more By Angus Liu Eisai officially launched its new U.S. headquarters just as the Japanese pharma looks to expand its commercial presence with an Aduhelm follow-up in Alzheimer’s disease by “building trust with the public.” read more By Heather Landi Incredible Health is growing leaps and bounds at a time when other digital health companies are tightening their belts, pressured by revenue declines and slowing venture capital funding. read more By Andrea Park A new artificial intelligence algorithm on the block is aiming to predict the risk of an accidental fall before it happens but for a very specific patient group: lower limb amputees. read more Resources Sponsored by: Catalent Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Thermo Fisher Scientific Set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 
